Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort

Systemic Lupus Erythematosus

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort

Rheumatology (Oxford).

Segura BT, Bernstein BS, McDonnell T, Wincup C, Ripoll V, Giles I, Isenberg D, Rahman A

doi: 10.1093/rheumatology/kez292.

Rheumatoid Arthritis

Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

J Rheumatol

van der Heijde D, Kartman CE, Xie L, Beattie S, Schlichting D, Mo D, Durez P, Tanaka Y, Fleischmann R

doi: 10.3899/jrheum.210346

Juvenile Idiopathic Arthritis

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Rheumatology (Oxford).

Chhabra A, Robinson C, Houghton K, Cabral DA, Morishita K, Tucker LB, Petty RE, Larché M, Batthish M, Guzman J

doi: 10.1093/rheumatology/keaa118.

COMMENTED

Rheumatoid Arthritis

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

doi: 10.1186/s13075-019-2059-8.

Rheumatoid Arthritis

Association between Vitamin D deficiency and disease activity, disability and radiographic progression in early rheumatoid arthritis. The ESPOIR cohort

J Rheumatol.

Mouterde G, Gamon E, Rincheval N, Lukas C, Seror R, Berenbaum F, Dupuy AM, Daien C, Daurès JP, Combe B

doi: 10.3899/jrheum.190795.

Melanoma and Skin Cancer

Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis

JAMA Dermatol.

Esse S, Mason KJ, Green AC, Warren RB

doi: 10.1001/jamadermatol.

Further Publications Rheumatology

Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

Arthritis Rheumatol

McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ

doi: 10.1002/art.42010

Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients

J Am Acad Dermatol.

Mertens JS, Thurlings RM, Kievit W, Seyger MMB, Radstake TRD, de Jong EMGJ

doi: 10.1016/j.jaad.2017.05.018.

Rheumatoid Arthritis

Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020

Rheumatology (Oxford)

Norris-Grey C, Cambridge G, Moore S, Reddy V, Leandro M

doi: 10.1093/rheumatology/keab248

Related content

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort

Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Association between Vitamin D deficiency and disease activity, disability and radiographic progression in early rheumatoid arthritis. The ESPOIR cohort

Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis

Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients

Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020